ReviewClinical and translational medicine2026
Glycolysis enzymes and cellular lactylation in tumour.
Review in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolomic Insights into Head and Neck Cancer: Recent Advances and Future Directions.Current oncology (Toronto, Ont.) · 2026Review
- Glycolysis enzymes and cellular lactylation in tumour.Clinical and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cellular lactylation, a recently identified post-translational modification, has emerged as a crucial regulator in various biological processes, particularly in cancer. The discovery of lactylation provides a new perspective for understanding the functional significance of the Warburg effect in tumour cells. Enzymes involved in the glycolytic pathway modulate lactylation, influencing tumour genesis and progression. This review explores the intricate relationship between glycolysis, lactylation and tumour biology, with a focus on how enzymes participating in glycolysis impact lactylation in cancer cells. We discuss how glycolytic enzymes regulate lactylation and highlight their broader implications in tumour biology. The role of lactylation in shaping the tumour microenvironment underscores its increasing significance as a biomarker for cancer prognosis and a target for therapeutic intervention. Therefore, we also summarised the potential of targeting lactylation as a cancer therapy strategy. KEY POINTS: Glycolytic enzymes regulate lactylation in cancer cells. Lactylation drives tumour growth, metastasis, immune evasion and contributes to microenvironment remodelling Targeting lactylation holds promise for cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.